MWPCG
NBIX icon

Measured Wealth Private Client Group’s Neurocrine Biosciences NBIX Stock Holding History

Measured Wealth Private Client Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Hold
140
– – 0.01% 458
2026
Q1 		$18.4K Hold
140
– – 0.01% 495
2025
Q4 		$19.9K Hold
140
– – 0.01% 482
2025
Q3 		$19.7K Buy
+140
New +$19K 0.01% 474

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Measured Wealth Private Client Group's NBIX Position: Q2 2026 in Review

Measured Wealth Private Client Group held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 140 shares worth $23.6K. The position accounts for 0.01% of the portfolio, ranked #458.

Measured Wealth Private Client Group first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Measured Wealth Private Client Group held 140 shares of Neurocrine Biosciences worth $23.6K as of Q2 2026.
  • Measured Wealth Private Client Group left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #458 holding.
  • Measured Wealth Private Client Group first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.